Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2015 Mar 19

PMID 25785276

Citations 22

Authors

Chia-Hung Lin

Yun-Shien Lee

Yu-Yao Huang

Sheng-Hwu Hsieh

Zih-Syuan Chen

Chi-Neu Tsai

Affiliations

Soon will be listed here.

Abstract

Aim: The relationship between genetic polymorphisms of the glucagon-like peptide-1 (GLP-1) receptor (GLP1R) gene and unresponsiveness to GLP-1 analogue treatment in patients with poorly controlled type 2 diabetes mellitus (DM) is unclear.

Methods: Thirty-six patients with poorly controlled type 2 DM were enrolled and they received six days of continuous subcutaneous insulin infusion for this study. After the normalization of blood glucose in the first 3 days, the patients then received a combination therapy with injections of the GLP-1 analogue, exenatide, for another 3 days. All 13 exons and intron-exon boundaries of the GLP1R gene were amplified to investigate the association.

Results: The short tandem repeat at 8GA/7GA (rs5875654) had complete linkage disequilibrium (LD, with r2 = 1) with single nucleotide polymorphism (SNP) rs761386. Quantitative trait loci analysis of GLP1R gene variation with clinical response of GLP1 analogue showed the missense rs3765467 and rs761386 significantly associated with changes in the standard deviation of plasma glucose (SDPG(baseline) - SDPG(treatment with GLP-1 analogue)) (P = 0.041 and 0.019, resp.). The reported P values became insignificant after multiple testing adjustments.

Conclusion: The variable response to the GLP-1 analogue was not statistically correlated with polymorphisms of the GLP1R gene in patients with poorly controlled type 2 DM.

Citing Articles

Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women.

Bao X, Liu C, Liu H, Wang Y, Xue P, Li Y J Orthop Surg Res. 2024; 19(1):869.

PMID: 39716293 PMC: 11667832. DOI: 10.1186/s13018-024-05361-z.

Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.

Eghbali M, Alaei-Shahmiri F, Hashemi-Madani N, Emami Z, Mostafavi L, Malek M Adv Ther. 2024; 41(2):826-836.

PMID: 38172377 DOI: 10.1007/s12325-023-02761-1.

Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus.

Paz-Pacheco E, Nevado Jr J, la Paz E, Jasul Jr G, Aman A, Alejandro-Ribaya E J ASEAN Fed Endocr Soc. 2023; 38(1):31-40.

PMID: 37234931 PMC: 10207869. DOI: 10.15605/jafes.037.S8.

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.

Du J, Xi L, Zhang Z, Ge X, Li W, Peng W Front Endocrinol (Lausanne). 2023; 13:1097612.

PMID: 36686441 PMC: 9846071. DOI: 10.3389/fendo.2022.1097612.

Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.

Fang X, Miao R, Wei J, Wu H, Tian J Comput Struct Biotechnol J. 2022; 20:5935-5951.

PMID: 36382190 PMC: 9646750. DOI: 10.1016/j.csbj.2022.10.030.

References

Davis S, Johns D, Maggs D, Xu H, Northrup J, Brodows R . Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care. 2007; 30(11):2767-72. DOI: 10.2337/dc06-2532. View

Baggio L, Drucker D . Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6):2131-57. DOI: 10.1053/j.gastro.2007.03.054. View

Bode B . Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Clin Ther. 2008; 29 Suppl D:S135-44. DOI: 10.1016/j.clinthera.2007.12.013. View

Woodcock J, Lesko L . Pharmacogenetics--tailoring treatment for the outliers. N Engl J Med. 2009; 360(8):811-3. DOI: 10.1056/NEJMe0810630. View

Schafer S, Mussig K, Staiger H, Machicao F, Stefan N, Gallwitz B . A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia. 2009; 52(6):1075-82. DOI: 10.1007/s00125-009-1344-5. View

Pilgaard K, Jensen C, Schou J, Lyssenko V, Wegner L, Brons C . The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia. 2009; 52(7):1298-307. DOI: 10.1007/s00125-009-1307-x. View

Mussig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, Schafer S . Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes. 2009; 58(7):1715-20. PMC: 2699873. DOI: 10.2337/db08-1589. View

Arnolds S, Dellweg S, Clair J, Dain M, Nauck M, Rave K . Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010; 33(7):1509-15. PMC: 2890351. DOI: 10.2337/dc09-2191. View

Sathananthan A, Dalla Man C, Micheletto F, Zinsmeister A, Camilleri M, Giesler P . Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010; 33(9):2074-6. PMC: 2928367. DOI: 10.2337/dc10-0200. View

10.

Buse J, Bergenstal R, Glass L, Heilmann C, Lewis M, Kwan A . Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2010; 154(2):103-12. DOI: 10.7326/0003-4819-154-2-201101180-00300. View

11.

Moon M, Kim H, Park S, Kim D, Cho E, Park C . Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation. J Biol Chem. 2011; 287(6):3873-84. PMC: 3281735. DOI: 10.1074/jbc.M111.276808. View

12.

Lin C, Huang C, Tsai J, Hsieh S, Sun J, Huang B . Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan. Endocr J. 2011; 58(10):835-40. DOI: 10.1507/endocrj.ej11-0036. View

13.

Koole C, Wootten D, Simms J, Valant C, Miller L, Christopoulos A . Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol. 2011; 80(3):486-97. PMC: 3364496. DOI: 10.1124/mol.111.072884. View

14.

Smushkin G, Sathananthan M, Sathananthan A, Dalla Man C, Micheletto F, Zinsmeister A . Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes. 2012; 61(5):1082-9. PMC: 3331759. DOI: 10.2337/db11-1732. View

15.

Chang C, Tsai C, Tang C, Chen C, Lian J, Hu C . Mixed sequence reader: a program for analyzing DNA sequences with heterozygous base calling. ScientificWorldJournal. 2012; 2012:365104. PMC: 3385616. DOI: 10.1100/2012/365104. View

16.

Anderson S, Trujillo J, McDermott M, Saseen J . Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003). 2012; 52(4):466-71. DOI: 10.1331/JAPhA.2012.10217. View

17.

Kirkpatrick A, Heo J, Abrol R, Goddard 3rd W . Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor. Proc Natl Acad Sci U S A. 2012; 109(49):19988-93. PMC: 3523846. DOI: 10.1073/pnas.1218051109. View

18.

Doyle M, Greig N, Holloway H, Betkey J, Bernier M, Egan J . Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. Endocrinology. 2001; 142(10):4462-8. DOI: 10.1210/endo.142.10.8410. View

19.

Egan J, Clocquet A, Elahi D . The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002; 87(3):1282-90. DOI: 10.1210/jcem.87.3.8337. View

20.

Bode B, Tamborlane W, Davidson P . Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 2002; 111(5):69-77; quiz 27. DOI: 10.3810/pgm.2002.05.1200. View